trovafloxacin has been researched along with clavulanic acid in 7 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 3 (42.86) | 18.2507 |
2000's | 3 (42.86) | 29.6817 |
2010's | 1 (14.29) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Lombardo, F; Obach, RS; Waters, NJ | 1 |
Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
Bur, F; Donahue, PE; Luke, DR; Mintz, SJ; Smith, DL; Yellin, AE | 1 |
Chatwani, A; Dittrich, R; Koltun, W; Luke, DR; Martens, MG; Roy, S | 1 |
Kanayama, A; Kobayashi, I; Mochida, O; Naito, S; Saika, T; Tanaka, M; Tunoe, H | 1 |
Fernández, F; Martínez-Martínez, L; Perea, EJ | 1 |
2 trial(s) available for trovafloxacin and clavulanic acid
Article | Year |
---|---|
Trovafloxacin in the treatment of intra-abdominal infections: results of a double-blind, multicenter comparison with imipenem/cilastatin. Trovafloxacin Surgical Group.
Topics: Abdomen; Administration, Oral; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Bacterial Infections; Cilastatin; Clavulanic Acid; Double-Blind Method; Female; Fluoroquinolones; Humans; Imipenem; Injections, Intravenous; Male; Middle Aged; Naphthyridines; Penicillins; Prospective Studies; Protease Inhibitors; Surgical Wound Infection; Thienamycins; Treatment Outcome | 1998 |
Treatment of acute gynecologic infections with trovafloxacin. Trovafloxacin Surgical Group.
Topics: Acute Disease; Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Cefoxitin; Cephamycins; Clavulanic Acid; Double-Blind Method; Enterococcus; Female; Fluoroquinolones; Humans; Middle Aged; Naphthyridines; Pelvic Inflammatory Disease; Penicillins; Prospective Studies; Treatment Outcome | 1998 |
5 other study(ies) available for trovafloxacin and clavulanic acid
Article | Year |
---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Antimicrobial activity of gemifloxacin (SB-265805), a newer fluoroquinolone, against clinical isolates of Neisseria gonorrhoeae, including fluoroquinolone-resistant isolates.
Topics: Amoxicillin; Anti-Infective Agents; Ciprofloxacin; Clavulanic Acid; Drug Resistance, Microbial; Fluoroquinolones; Gemifloxacin; Gonorrhea; Humans; Levofloxacin; Naphthyridines; Neisseria gonorrhoeae; Norfloxacin; Ofloxacin | 2000 |
Relationship between haemolysis production and resistance to fluoroquinolones among clinical isolates of Escherichia coli.
Topics: Amoxicillin; Ampicillin; Animals; Anti-Infective Agents; Ciprofloxacin; Clavulanic Acid; Drug Resistance, Microbial; Escherichia coli; Fluoroquinolones; Gentamicins; Hemolysin Proteins; Hemolysis; Humans; Microbial Sensitivity Tests; Nalidixic Acid; Naphthyridines; Pefloxacin; Tetracycline | 1999 |